Recombinant Human LAMP2 Protein (C-6His)

Name: Recombinant Human LAMP2 Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-0325NP
Availability: InStock

BL-0325NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Lysosome-Associated Membrane Glycoprotein 2 is produced by our Mammalian expression system and the target gene encoding Leu29-Ile375 is expressed with a 6His tag at the C-terminus.
Accession	P13473
Synonym	Lysosome-Associated Membrane Glycoprotein 2; LAMP-2; Lysosome-Associated Membrane Protein 2; CD107 Antigen-Like Family Member B; CD107b; LAMP2
Gene Background	Lysosomal Associated Membrane Protein 2 (LAMP2) is a major component of lysosomal membranes. LAMP2 is a transmembrane glycoprotein about 110kDa. Mature human LAMP2 consists of a 347 amino acid (aa) intralumenal domain, a 24 aa transmembrane segment, and a 35 aa cytoplasmic tail . The lumenal domain is organized into two heavily N-glycosylated regions. Alternate splicing generates a human LAMP2 isoform (LAMP2B) with a substituted juxtamembrane lumenal region, cytoplasmic tail and transmenmbrane segment.LAMP2 itself can cleavage lysosomal luminal domain and degradation lysosomal. In the help of chaperone HSC73,LAMP2 mediates the lysosomal uptake in complex with cargo proteins and is required for the lysosomal destruction of autophagic vacuoles.
Molecular Mass	39.4 KDa
Apmol Mass	60-120 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Plays an important role in chaperone-mediated autophagy, a process that mediates lysosomal degradation of proteins in response to various stresses and as part of the normal turnover of proteins with a long biological half-live. Functions by binding target proteins, such as GAPDH and MLLT11, and targeting them for lysosomal degradation. Plays a role in lysosomal protein degradation in response to starvation. Required for the fusion of autophagosomes with lysosomes during autophagy. Cells that lack LAMP2 express normal levels of VAMP8, but fail to accumulate STX17 on autophagosomes, which is the most likely explanation for the lack of fusion between autophagosomes and lysosomes. Required for normal degradation of the contents of autophagosomes. Required for efficient MHCII-mediated presentation of exogenous antigens via its function in lysosomal protein degradation; antigenic peptides generated by proteases in the endosomal/lysosomal compartment are captured by nascent MHCII subunits. Is not required for efficient MHCII-mediated presentation of endogenous antigens.; Modulates chaperone-mediated autophagy. Decreases presentation of endogenous antigens by MHCII. Does not play a role in the presentation of exogenous and membrane-derived antigens by MHCII.; (Microbial infection) Supports the FURIN-mediated cleavage of mumps virus fusion protein F by interacting with both FURIN and the unprocessed form but not the processed form of the viral protein F.
Subcellular Location	Cell membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Cytoplasmic vesicle, autophagosome membrane. Note=This protein shuttles between lysosomes, endosomes, and the plasma membrane.
Protein Families	LAMP family
Database References	HGNC: 6501 OMIM: 300257 KEGG: hsa:3920 UniGene: PMID: 28729403 Results demonstrated that LAMP2 expression levels correlated with tumor histological differentiation and TNM stages. PMID: 28453465 Since effective regimens are readily available timely psychiatric evaluation is warranted in all newly diagnosed subjects with LAMP2 mutations, regardless of whether they show the typical Danon disease medical (cardiac) symptoms or not. PMID: 28627787 identified LAMP-2 as an endocytic receptor on monocyte-derived dendritic cells (MoDC) that routes cargo into unusual Ag processing pathways, which reduces surface expression of Ag-derived peptides while selectively enriching Ag within immunogenic exosome; this novel pathway has implications for the initiation of immune responses both locally and at distant sites PMID: 28607115 The results provide a new insight that LAMP-2 contributes to the ROS clearance and cell death induced by Zn(2+) treatment, which would help us to get a better understanding of Zn(2+)-induced toxicity in respiratory system. PMID: 28483530 overexpression assists neuroendocrine differentiation of prostate cancer cells induced by serum deprivation and facilitates autophagy activity PMID: 27627761 Genetic analysis identified 2 novel LAMP2 gene mutations. In Family A, a G-A transition (c.962G > A) leading to a nonsense mutation at codon 321 (p.Trp321Ter), and in Family B, a one-nucleotide insertion (c.973insC) leading to a full frame-shift (p.Pro324+24X) was detected in exon 8 of the LAMP2 gene. PMID: 27179547 intracellular Salmonella recruit the host proteins LAMP-2A and Hsc73, key components of the host protein turnover pathway known as chaperone-mediated autophagy involved in transport of cytosolic proteins to the lysosome for degradation. PMID: 27932462 3 novel nonsense mutations (p.Q240X, p.S250X, and p.G22X) were found in LAMP2 associated with early onset Danon disease with hypertrophic cardiomyopathy. LAMP2 expression was absent in both cardiac and skeletal muscle samples of the first proband and severely decreased LAMP2 expression in the skeletal muscle samples of the second proband. PMID: 27460667 Collectively, the present study shows that impaired Lamp2a expression in hepatocellular carcinoma contributes to tumor cell viability and promotes tumor growth and recurrence. PMID: 27840904 Increased expression of LAMP2 has been observed in peripheral blood mononuclear cells of coronary artery disease patients compared to the control group. PMID: 27923262 Knockdown of LAMP2A, a CMA-related protein, and TSG101, an mA-related protein, significantly but only partially decreased the punctate accumulation of GAPDH-HT in AD293 cells and primary cultured rat cortical neurons. PMID: 27377049 miR-487b-5p regulates temozolomide resistance of lung cancer cells through LAMP2-mediated autophagy. PMID: 27097129 Up-regulation of LAMP2 is associated with carcinogenesis and progression of Salivary Adenoid Cystic Carcinoma. PMID: 26350055 In our study of the EOG in Danon disease, we show for the first time to our knowledge that a LAMP2 mutation may cause a primary retinal pigment epitheliopathy. PMID: 26398689 LAMP-2C serves as a natural inhibitor of chaperone-mediated autophagy that can selectively skew MHCII presentation of cytoplasmic antigens PMID: 26856698 In the early stages of Parkinson's disease, with LAMP2A selectively reduced in association with increased alpha-synuclein, and decreased levels of heat shock cognate protein 70. PMID: 25594542 This study showed that LAMP2 upregulation occurs in vitro and in vivo in neoplastic cells. PMID: 26658462 Down-regulation of LAMP2A expression could inhibit cell proliferation in multiple myeloma cells PMID: 25940285 Data show thart lysosome-associated membrane protein type 2a (LAMP-2A) forms a coiled coil helix trimer in n-dodecylphosphocholine micelle, and protein substrates interact with its cytosolic tail. PMID: 25342746 LAMP2 has a role in differentiation of primary biliary cirrhosis PMID: 24007661 Patient B harbored a frame-shift deletion mutation in exon 3 (c.396delA) leading to a truncated LAMP2 protein PMID: 24691104 down-regulation of LAMP2A could reduce the resistance of breast cancer cells to paclitaxel PMID: 24721399 LAMP2 is investigated as a marker of Epstein-Barr virus-mediated B lymphocyte transformation in lysosomal storage diseases. PMID: 24068328 Autoantibodies to hLAMP-2 that bind native glomerular but not neutrophil hLAMP-2 are found in patients with ANCA-negative pauci-immune focal necrotizing glomerulonephritis. PMID: 24203998 These data support a positive relationship between anti-LAMP-2 antibody and cutaneous vasculitis. PMID: 23704322 Decreased levels of the chaperone-mediated autophagy proteins LAMP-2A and hsc70 (CMA) in Parkinson's disease brain samples suggests compromised alpha-synuclein degradation by CMA and may underpin the Lewy body pathology. PMID: 23492776 indicate that monoclonal antibodies specific to CD107a (LAMP-1) or CD107b (LAMP-2) enhanced LPS-induced IL-8 secretion of THP-1 cells. PMID: 23603048 expression of LAMP2A was observed in breast tumor tissues of all patients under investigation, suggesting a survival mechanism via chaperone-mediated autophagy and LAMP2A. PMID: 22874552 Studies suggest that Hsc70 and lysosome-associated protein 2A (LAMP-2A) through chaperone-mediated autophagy (CMA) play a role in the clearance of Htt and suggest a novel strategy to target the degradation of mutant huntingtin (Htt). PMID: 23071649 There is a progressive, age-related decrease of LAMP-2 gene expression in the peripheral leukocytes of healthy subjects, indicating a trend of decreasing autophagy activities with aging. PMID: 22732524 variants within LAMP-2 gene promoter may be linked to Parkinson disease. PMID: 22867958 findings indicated that patients with Danon disease caused by mutations in exon 1 - 8 manifested as a typically severe phenotype, while patients with mutations in exon 9 of the LAMP2B isoform presented with a relatively benign phenotype PMID: 22541782 A novel LAMP2 mutation (c.940delG) in Danon disease patients, which results in a putatively truncated protein. PMID: 22365987 decreased LAMP-2 gene expression and increased LC3 gene expression may contribute to the pathogenesis of sporadic Parkinson's disease PMID: 21514572 Peripheral leukocyte LAMP-2 expression is significantly inceased in coronary artery disease. PMID: 21462217 intrafamilial phenotypic variability in Danon disease is related to a novel LAMP-2 mutation PMID: 21161685 gene deficient B cells exhibit altered MHC class II presentation of exogenous antigens PMID: 20518820 Lysosome-associated membrane protein (LAMP2) cardiomyopathy is an X-linked and highly progressive myocardial storage disorder associated with diminished survival, which clinically resembles sarcomeric hypertrophic cardiomyopathy. PMID: 20920663 The LAMP2 microdeletion mechanism appears to involve 1 Alu-mediated unequal recombination and 2 chromosomal breakage points involving TA-rich repeat sequences. PMID: 20173215 Danon disease is caused by deficiency of lysosome-associated membrane protein-2 (LAMP-2). PMID: 20513107 Data show that the BCG phagosome is relatively depleted in LAMP-2, NPC1, flotillin-1, vATPase, and syntaxin 3. PMID: 19815536 This studu showed decreased LAMP2 expression in the sketal muscle in female patient with Danon disease. PMID: 14561493 The glycogen-storage cardiomyopathy produced by LAMP2 or PRKAG2 mutations resembles hypertrophic cardiomyopathy but is distinguished by electrophysiological abnormalities PMID: 15673802 role for the lysosomal Lamp-2a-hsc70 complex in promoting immunological recognition and antigen presentation PMID: 15894275 LAMP2 mutations may account for significant proportion of cases of hypertrophic cardiomyopathy children, especially when skeletal myopathy and/or Wolff-Parkinson-White syndrome is present. Danon disease may be underrecognized in pediatric cardiology. PMID: 16144992 Our report further expands the phenotype of Danon disease by describing retinopathy in 3 cases. A thorough clinical examination, including ophthalmic investigation, is needed in all cases of Danon disease. PMID: 17296900 The biopsied muscle specimen stained for LAMP2 and confirmed the diagnosis of vacuolar myopathy with dilated cardiomyopathy. PMID: 17873513 Analysis of the lysosome-associated membrane protein-2 (LAMP-2) gene detected a novel mutation, confirming a diagnosis of Danon disease. PMID: 17899313 A new intronic mutation in the LAMP2 gene in French Candian family leading to out frame skppin of exon 7 in Dannon disease. PMID: 18004770

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.